| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d916a22c5636afca7e73db667e90663 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-852
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-828 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eff00bdb6f74d9522952fd5a19d2b4c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1855c97e1cfd8381b03bf8e17215de1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1db7e5a3f7ea64352b25cf482d637b18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ad0b081b28ac65c7af53d4174d9d92a |
| publicationDate |
2021-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113645996-A |
| titleOfInvention |
Anti-claudin 18 antibody and method of use |
| abstract |
The present invention discloses antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for antibody-based immunotherapy of diseases associated with aberrant expression of CLDN18.2. |
| priorityDate |
2019-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |